Arbutus withholds 100,508 shares for director's options

The issuer withheld 100,508 otherwise issuable shares to satisfy the aggregate exercise prices.

Rhea-AI Filing Summary

On September 18, 2026, Arbutus Biopharma Corp director Roger Sawhney exercised options to acquire 52,533 common shares at $3.34 and 78,800 common shares at $4.24. The issuer withheld 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. The 52,533-share exercise related to an option for 157,600 shares that vests in thirds on the first three anniversaries of August 4, 2025, subject to continuous service; the 78,800-share option was fully vested and exercisable as of its June 8, 2026 grant date.

Insider Trade Summary

131,333 shares exercised/converted

Exercise 5 txns

Insider Sawhney Roger

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	52,533	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F3	78,800	$0.00	$0.00
Exercise	Common Shares	52,533	$3.34	$175K
Exercise	Common Shares	78,800	$4.24	$334K
Exercise Price or Tax Liability	Common Shares F1	100,508	$5.07	$510K

Holdings After Transaction: Stock Option (Right to Buy) — 105,067 contracts (Direct); Common Shares — 30,825 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.
2. F2. The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the August 4, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date.
3. F3. The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date.

Key Figures

Shares acquired through option exercise: 52,533 shares Shares acquired through option exercise: 78,800 shares Shares withheld: 100,508 shares +2 more

5 metrics

Shares acquired through option exercise 52,533 shares At an exercise price of $3.34 per share on September 18, 2026

Shares acquired through option exercise 78,800 shares At an exercise price of $4.24 per share on September 18, 2026

Shares withheld 100,508 shares Withheld by the issuer to satisfy the aggregate exercise prices

Option right to purchase 157,600 shares Option granted August 4, 2025, with vesting over three years subject to continuous service

Fully vested and exercisable option 78,800 shares As of the June 8, 2026 grant date

Key Terms

aggregate exercise prices, vests over a three-year period, continuous service, fully vested and exercisable

4 terms

aggregate exercise prices financial

"to satisfy the aggregate exercise prices"

vests over a three-year period financial

"vests over a three-year period"

continuous service technical

"subject to the Reporting Person's continuous service as of each vesting date"

fully vested and exercisable financial

"was fully vested and exercisable as of the June 8, 2026 grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ABUS shares did director Roger Sawhney acquire through option exercises?

Roger Sawhney acquired 52,533 common shares at $3.34 and 78,800 common shares at $4.24 through option exercises on September 18, 2026.

How many shares did Arbutus withhold from Roger Sawhney's option exercises?

Arbutus Biopharma Corp withheld 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.

What were the vesting terms of Roger Sawhney's ABUS options?

The option representing the right to purchase 157,600 shares vests over three years, with one-third vesting on each of the first, second and third anniversaries of August 4, 2025, subject to continuous service on each vesting date. The 78,800-share option was fully vested and exercisable as of the June 8, 2026 grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/23/2026 - 08:32 PM Accepted by SEC EDGAR 09/23/2026 - 08:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawhney Roger

(Last) (First) (Middle)

C/O ARBUTUS BIOPHARMA CORPORATION

701 VETERANS CIRCLE

(Street)

WARMINSTER PENNSYLVANIA 18974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/18/2026		M		52,533	A	$3.34	52,533	D
Common Shares	09/18/2026		M		78,800	A	$4.24	131,333	D
Common Shares	09/18/2026		F(1)		100,508	D	$5.07	30,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.34	09/18/2026		M			52,533	(2)	08/04/2035	Common Shares	52,533	$0	105,067	D
Stock Option (Right to Buy)	$4.24	09/18/2026		M			78,800	06/08/2026(3)	06/08/2036	Common Shares	78,800	$0	0	D

Explanation of Responses:

1. The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.

2. The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the August 4, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date.

3. The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date.

Remarks:

	/s/ Tuan Nguyen as attorney-in-fact for Roger Sawhney	09/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)